查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008499

肉瘤治疗市场：2026-2032年全球市场预测（按药物类别、给药途径、治疗方法、适应症和最终用户划分）

Sarcoma Drugs Market by Drug Class, Route Of Administration, Treatment Modality, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年肉瘤治疗市场价值 18 亿美元，预计到 2026 年将成长至 19.5 亿美元，复合年增长率为 9.32%，到 2032 年将达到 33.6 亿美元。

主要市场统计数据
基准年 2025 18亿美元
预计年份：2026年 19.5亿美元
预测年份 2032 33.6亿美元
复合年增长率 (%) 9.32%

透过将不同疾病类型的科学进步与临床、监管和商业性现实相结合，我们旨在阐明肉瘤治疗策略的背景。

肉瘤治疗是肿瘤学领域最复杂、技术要求最高的领域之一，涵盖罕见的组织学亚型、多种分子驱动因素以及需要多学科协作的治疗路径。本执行摘要首先将肉瘤置于更广泛的肿瘤学生态系统中进行探讨。在这个治疗领域，分子标靶治疗、免疫肿瘤疗法和先进的细胞毒性疗法与基因组学和组织病理学诊断技术的进步相辅相成。这对医疗保健系统的研发人员和相关人员具有巨大的实际意义。有关临床开发、监管策略和市场准入的决策必须考虑到不同的患者群体、不断发展的生物标记框架以及不断变化的支付方预期。

分子谱分析、适应性试验设计和监管柔软性的进步如何重塑肉瘤疗法的开发路径和商业策略。

肉瘤领域正经历着由科学、监管和商业性因素共同驱动的变革，这些变革正在重塑相关人员对专案优先顺序的设定和资源的分配方式。在科学层面，基因组分析和单细胞技术的进步正在加速标靶发现和患者分层，从而能够在分子定义的队列中开展小规模、效率更高、信噪比更高的临床试验。同时，细胞疗法和免疫肿瘤学联合策略的成熟正在扩大治疗途径的选择范围，使其超越传统的细胞毒性疗法。这些进展从根本上改变了临床试验的设计，促进了适应性通讯协定和平台试验的开展，从而缩短了研发週期，并加深了对罕见亚型的认识。

2025 年美国关税趋势对肉瘤治疗商业化过程中供应链韧性、筹资策略和价格谈判的影响。

美国将于2025年前实施的一系列关税措施，其累积影响将为参与肉瘤治疗药物研发和分销的赞助商、製造商和医疗系统带来新的考量。影响活性成分、关键原材料和某些医疗设备的关税可能会增加整个供应链的成本，促使各方重新评估筹资策略和製造地。在许多情况下，製造商正透过重新优化供应商网路、确保原料药采购的冗余性以及加快区域生产投资来应对，以降低进口关税带来的影响并维持可预测的生产前置作业时间。

这种多维细分框架将药物类别、适应症、给药途径、最终用户和治疗方法联繫起来，有助于确定优先事项和製定产业计画。

細項分析为相关人员提供了多种观点，以便他们确定投资优先顺序并调整研发计划。按药物类别划分，主要类别包括抗血管新生疗法、化疗、荷尔蒙疗法、免疫疗法和标靶治疗。抗血管新生疗法进一步细分为PDGF抑制剂和VEGF抑制剂；化疗进一步分为烷化剂、细胞週期蛋白药物、抗代谢药物和拓朴异构酶抑制剂；免疫疗法包括细胞疗法、癌症疫苗、查核点抑制剂和细胞激素疗法；标靶治疗包括CDK4/6抑制剂、mTOR抑制剂、PARP抑制剂和蛋白酪氨酸激酶抑制剂。每个药物类别都意味着不同的临床试验设计、安全性监测要求、生产复杂性和对支付方的价值提案；因此，研发团队必须使其治疗方法选择与目标适应症和预期治疗方案相符。

关键地区的监管多样性、临床能力和报销实际情况如何影响战略部署计划和证据收集重点？

区域趋势对肉瘤治疗的临床开发、监管策略和商业性实施有显着影响。美洲地区拥有先进的诊断基础设施、完善的临床试验网路以及要求清晰成本效益说明的支付方环境，因此成为註册试验和早期商业性上市的重点区域。而欧洲和中东及非洲地区（EMEA）的相关人员则面临不同的监管路径、异质的报销体係以及诊断能力的差异。在这些地区取得成功通常需要模组化的准入策略，以应对各国特定的卫生技术评估（HTA）流程以及罕见病专科中心的能力缺口。在亚太地区，肿瘤研究的快速发展、临床试验参与度的提高以及不断变化的报销框架既带来了机会，也带来了挑战，因此需要特别关注本地化生产、区域监管协调以及符合当地文化的病人参与。

创新与规模之间的平衡：跨国製药公司、敏捷生物技术公司和合作伙伴关係模式在推动肉瘤治疗的策略优势。

肉瘤治疗领域的竞争格局融合了成熟的跨国肿瘤公司的规模和研发能力，以及专业生物技术公司的敏捷性和分子层面的专注性。大型製药企业拥有丰富的研发经验、全球监管经验和整合的商业管道，能够快速将后期研发专案推向市场。它们的优势包括能够为大规模註册项目提供资金，并与复杂的支付方进行合约谈判。相较之下，小规模的生物技术公司往往专注于特定作用机制的创新，快速迭代和完善以生物标誌物为导向的策略，并为寻求产品组合互补的大型机构创造高价值的合作机会。因此，策略联盟、授权协议和联合开发伙伴关係十分常见，使得公司之间能够共享联合治疗策略以及专业的生产和临床技术。

肉瘤专案开发公司和相关人员在协调临床试验设计、供应弹性、支付方证据生成和伙伴关係管治面临的实际策略挑战。

产业领导者必须采取果断行动，将科学预期转化为可持续的患者获益，同时管控商业性和营运风险。首先，他们必须使早期研发与明确的市场进入假设保持一致，这些假设应明确目标组织类型、生物标记策略和理想的治疗环境。这种一致性可以减少不必要的投资，并加快与支付方的对话。其次，他们应投资于模组化和适应性试验设计，以便在分子定义的队列中进行假设检验，加速概念验证（PoC）结果的获得，并保留与原料药和标靶治疗联合治疗的策略选择。第三，他们应透过原料药来源多元化、探索区域製造伙伴关係以及检验依赖医疗设备给药途径的紧急时应对计画来建构具有韧性的供应链，从而减轻关税和物流中断的影响。

采用稳健的混合方法研究方法，结合专家访谈、二手证据三角验证和基于情境的分析，以确保实用见解和可重复性。

本研究整合了专家访谈、文献综述以及对临床、监管和商业性讯号的结构化分析，从而整体情况了肉瘤治疗现状。一级资讯来源包括对肿瘤学家、临床试验主要研究者、监管专家和市场进入负责人的访谈，确保临床实践模式和支付方的期望能够反映在对科学和营运趋势的解读中。次要资讯来源包括同侪审查的临床文献、监管指南、会议记录以及与药物研发相关的技术文件。这些资讯来源经过交叉检验，以检验研究结果并阐明新治疗方法的背景。

将策略重点转化为永续的临床影响，并解决肉瘤领域在营运、监管和支付方方面面的挑战。

总之，肉瘤治疗领域融合了引人入胜的科学机会和实际操作的复杂性。分子表征、免疫疗法设计和联合治疗的进步拓宽了可行的治疗策略范围，但成功取决于临床开发、监管规划和商业化准备的严格协调。按药物类别、适应症、给药途径、治疗方法和最终用户进行精准细分，有助于集中资源并提高临床试验效率。区域策略必须体现诊断能力、监管路径和支付方期望的差异。此外，面对关税和地缘政治压力，供应链的韧性也变得日益重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肉瘤治疗市场：依药物类别划分

  • 抗血管新生疗法
    • PDGF抑制剂
    • VEGF抑制剂
  • 化疗
    • 烷化剂
    • 细胞週期蛋白
    • 抗代谢物
    • 拓朴异构酶抑制剂
  • 荷尔蒙疗法
  • 免疫疗法
    • 细胞疗法
    • 癌症疫苗
    • 查核点抑制剂
    • 细胞激素疗法
  • 分子标靶治疗
    • CDK4/6抑制剂
    • mTOR抑制剂
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章：肉瘤治疗药物市场：依给药途径划分

  • 肌肉内部
  • 静脉
  • 口服
  • 皮下

第十章：依治疗方法分類的肉瘤治疗市场

  • 联合治疗
    • 化疗+免疫疗法
    • 化疗+标靶治疗
    • 免疫疗法+标靶治疗
  • 单药治疗

第十一章 肉瘤治疗市场：依适应症划分

  • 骨癌
    • 软骨肉瘤
    • 伊文氏肉瘤
    • 骨癌
  • 胃肠道基质肿瘤
  • 卡波西氏肉瘤
  • 软组织肉瘤
    • 平滑肌肉瘤
    • 脂肪肉瘤
    • 横纹肌肉瘤
    • 滑膜肉瘤

第十二章 肉瘤治疗市场：依最终使用者划分

  • 门诊手术中心
  • 居家照护
  • 医院
  • 专科诊所

第十三章 肉瘤治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肉瘤治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 肉瘤治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肉瘤治疗市场

第十七章：中国肉瘤治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • AgonOx
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996FA

The Sarcoma Drugs Market was valued at USD 1.80 billion in 2025 and is projected to grow to USD 1.95 billion in 2026, with a CAGR of 9.32%, reaching USD 3.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.80 billion
Estimated Year [2026] USD 1.95 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 9.32%

Setting the context for sarcoma therapeutics strategy by aligning scientific advances with clinical, regulatory and commercial realities across heterogeneous disease types

Sarcoma therapeutics represent one of oncology's most complex and technically demanding areas, spanning rare histologies, heterogeneous molecular drivers and treatment pathways that require multidisciplinary coordination. This executive summary opens by situating sarcoma within the broader oncology ecosystem: a therapeutic domain where targeted molecular approaches, immuno-oncology modalities and refined cytotoxic regimens intersect with diagnostic advances in genomics and histopathology. The practical consequences for developers and health system stakeholders are profound; decisions around clinical development, regulatory strategy and market access must incorporate heterogeneous patient populations, evolving biomarker frameworks and shifting payer expectations.

Clinical progress has been uneven by histologic subtype, but recent years have delivered a richer understanding of disease biology, enabling more precise interventions in previously intractable presentations. Consequently, stakeholders must balance long-standing standards of care with novel mechanisms that may offer incremental or transformational benefit depending on the indication. This introduction frames the remainder of the analysis by highlighting the interplay of scientific innovation, stakeholder incentives and operational constraints that shape strategic choices across drug class, indication, administration route and treatment modality. It also underscores the imperative for commercially minded teams to integrate cross-functional intelligence-clinical, regulatory, supply chain and reimbursement-to navigate a fast-moving therapeutic landscape effectively.

How advances in molecular profiling, adaptive trial design, and regulatory pragmatism are reshaping development pathways and commercial strategies in sarcoma therapeutics

The sarcoma landscape is undergoing transformative shifts driven by converging scientific, regulatory and commercial forces that are reshaping how stakeholders prioritize programs and allocate resources. At the scientific level, enhanced genomic profiling and single-cell technologies have accelerated target discovery and patient stratification, enabling smaller, more efficient trials with higher signal-to-noise for molecularly defined cohorts. Concurrently, the maturation of cell therapy and combination immuno-oncology strategies is expanding the set of plausible therapeutic pathways beyond traditional cytotoxic regimens. These advances are changing trial design fundamentals, encouraging adaptive protocols and platform trials that reduce timelines and improve learning across rare subtypes.

From a regulatory perspective, agencies are signaling greater willingness to engage on novel endpoints, accelerated approval pathways and conditional licensing for rare diseases, provided there is robust post-approval evidence generation. This regulatory pragmatism incentivizes earlier and clearer alignment between developers and regulators on surrogate endpoints, real-world evidence collection and risk mitigation strategies. Commercially, payers and procurement systems are increasingly demanding transparent value narratives and outcomes-based contracting for high-cost interventions, which favors developers who can demonstrate durable benefit and manageable safety profiles. Together, these shifts underscore a new operating model for sarcoma programs: rapid biomarker-enabled segmentation, flexible clinical proof-of-concept approaches, and integrated downstream planning for access and lifecycle management.

Implications of US tariff dynamics through 2025 for supply chain resilience, sourcing strategies, and pricing negotiations in sarcoma drug commercialization

The cumulative effect of United States tariff measures implemented through 2025 has introduced new considerations for sponsors, manufacturers and health systems engaged in sarcoma drug development and distribution. Tariffs affecting active pharmaceutical ingredients, critical raw materials and certain medical equipment can raise incremental costs along the supply chain, prompting reassessments of sourcing strategies and manufacturing footprints. In many cases, manufacturers respond by re-optimizing supplier networks, building redundancy into API sourcing and accelerating regional manufacturing investments to mitigate exposure to import levies and to preserve predictable production lead times.

Beyond direct cost impacts, tariffs influence commercial negotiation dynamics with payers and distributors. Where reimbursement is tightly constrained, even modest cost increases can alter pricing strategies and contract terms. Procurement teams may prioritize suppliers with localized supply chains to reduce tariff-related volatility, and developers may find added leverage in forming toll-manufacturing partnerships or licensing arrangements that localize production closer to end markets. Regulatory clearance processes and quality oversight remain paramount; any rapid manufacturing relocation must maintain compliance with Good Manufacturing Practice and ensure supply continuity for patients with few therapeutic alternatives. Ultimately, the tariff environment increases the strategic value of robust supply chain planning, scenario modeling and early engagement with procurement and manufacturing partners to safeguard access and preserve commercial viability.

A multidimensional segmentation framework linking drug classes, indications, administration routes, end users and treatment modalities to inform prioritization and operational planning

Segmentation analysis reveals multiple lenses through which stakeholders can prioritize investment and tailor development plans. When examining drug class, key categories include Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy; Antiangiogenic Therapy subdivides into PDGF Inhibitors and VEGF Inhibitors, Chemotherapy further separates into Alkylating Agents, Anthracyclines, Antimetabolites, and Topoisomerase Inhibitors, Immunotherapy encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, and Cytokine Therapy, and Targeted Therapy includes CDK4/6 Inhibitors, MTOR Inhibitors, PARP Inhibitors, and Tyrosine Kinase Inhibitors. Each drug-class grouping implies different clinical trial designs, safety monitoring needs, manufacturing complexity and payer value propositions, so development teams should align modality selection with the intended indication and expected line of therapy.

Indication-based segmentation distinguishes Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma, and Soft Tissue Sarcoma; within Bone Sarcoma, clinicians and developers consider Chondrosarcoma, Ewing Sarcoma, and Osteosarcoma as distinct biological entities with differing therapeutic responsiveness, while Soft Tissue Sarcoma includes Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, and Synovial Sarcoma, each demanding tailored clinical endpoints and histology-specific consideration. Route of administration segmentation covers Intramuscular, Intravenous, Oral, and Subcutaneous options, which shape patient adherence expectations, outpatient versus inpatient delivery models, and device or formulation development needs. End user segmentation identifies Ambulatory Surgical Centers, Home Care environments, Hospitals, and Specialty Clinics as primary delivery settings, influencing channel strategies, training requirements and reimbursement pathways. Treatment modality differentiation between Combination Therapy and Monotherapy, with Combination Therapy including Chemotherapy Plus Immunotherapy, Chemotherapy Plus Targeted, and Immunotherapy Plus Targeted approaches, drives decisions on clinical coordination, safety overlap management and commercial collaboration frameworks between co-developers. By integrating these segmentation axes, organizations can map development choices to operational constraints and market access realities, enabling prioritized investments where clinical need, biological plausibility and practicable deployment converge.

How regional regulatory diversity, clinical capacity and reimbursement realities across major geographies shape strategic rollout plans and evidence generation priorities

Regional dynamics materially influence clinical development, regulatory strategy and commercial execution across sarcoma therapeutics. In the Americas, the landscape is characterized by advanced diagnostic infrastructure, well-established clinical trial networks and a payer environment that demands clear cost-effectiveness narratives, which together make it a focal point for registrational studies and early commercial launches. Transitioning to Europe, Middle East & Africa, stakeholders encounter diverse regulatory pathways, heterogenous reimbursement systems and varying levels of diagnostic capability; success in this region often requires modular access strategies that address country-level HTA processes and capacity gaps in rare disease centers of excellence. In the Asia-Pacific region, rapid investment in oncology research, expanding clinical trial participation and evolving reimbursement frameworks create both opportunity and complexity, with particular attention needed on local manufacturing, regional regulatory harmonization and culturally appropriate patient engagement.

Across these geographic areas, clinical trial enrollment logistics, availability of specialized sarcoma centers, and regional variations in histologic prevalence all shape trial feasibility and post-approval adoption. Accordingly, successful programs adopt phased regional strategies that leverage early wins in capacity-dense markets while simultaneously investing in evidence generation, local stakeholder engagement and manufacturing adjustments to support broader rollout. This geographically nuanced approach helps ensure that clinical data, regulatory submissions and commercial readiness progress in parallel and that regional reimbursement barriers are anticipated and addressed proactively.

Balancing innovation and scale: the strategic advantages of multinational developers, nimble biotechs, and collaborative partnership models in advancing sarcoma therapies

The competitive landscape in sarcoma therapeutics blends the scale and development capacity of established multinational oncology firms with the agility and molecular focus of specialty biotechs. Large pharma players bring extensive development expertise, global regulatory experience, and integrated commercial channels that accelerate late-stage programs to market; their strengths include ability to underwrite expansive registrational programs and to negotiate complex payer arrangements. In contrast, smaller biotech companies often drive innovation in niche mechanisms, rapidly iterate on biomarker-directed strategies, and create high-value partnering opportunities for larger organizations seeking to complement their portfolios. Strategic alliances, licensing deals and co-development partnerships are therefore common, enabling combination strategies and cross-company access to specialized manufacturing or clinical expertise.

Investors and corporate development teams should track not only pipeline breadth but also platform capabilities, biomarker development resources, and manufacturing readiness. Companies with strong translational medicine functions and access to comprehensive patient registries and histology-specific networks are better positioned to execute small, high-impact trials. Additionally, firms that demonstrate operational excellence in cell therapy logistics, companion diagnostic co-development, or novel formulation delivery stand to differentiate in commercialization discussions with payers and providers. Ultimately, winning companies will combine scientific differentiation with pragmatic execution: robust clinical programs, validated companion diagnostics where appropriate, and credible commercialization blueprints that address the end-to-end patient journey.

Practical strategic imperatives for developers and stakeholders to align clinical design, supply resilience, payer evidence generation and partnership governance for sarcoma programs

Industry leaders should act decisively to translate scientific promise into durable patient benefit while managing commercial and operational risk. First, align early-stage development with a clear go-to-market hypothesis that defines target histologies, biomarker strategies and preferred care settings; this alignment reduces wasted investment and accelerates payer conversations. Second, invest in modular and adaptive trial designs that enable hypothesis testing across molecularly defined cohorts, accelerate proof-of-concept readouts and preserve optionality for combination strategies with immunotherapies or targeted agents. Third, build resilient supply chains by diversifying API sources, considering regional manufacturing partnerships, and validating contingency plans for device-dependent administration routes to mitigate tariffs and logistical disruptions.

In parallel, prioritize evidence generation that meets payer needs: integrate health economics endpoints and quality-of-life measures into pivotal development programs, and plan for real-world data collection that supports durability claims post-approval. Engage payers, providers and centers of excellence early to shape acceptable endpoints and to secure pathways for access. For companies pursuing combination strategies, establish clear co-development agreements that align incentives and responsibilities for safety monitoring, data sharing and commercialization. Finally, strengthen patient engagement and advocacy partnerships to streamline trial recruitment, enhance retention and incorporate patient-centric outcomes into product value narratives. These combined actions will improve the probability of regulatory success, accelerate market adoption and foster sustainable value capture.

A robust mixed-methods research approach combining primary expert elicitation, secondary evidence triangulation, and scenario-based analysis to ensure actionable and reproducible insights

This research synthesizes primary expert interviews, secondary literature review and structured analysis of clinical, regulatory and commercial signals to provide a comprehensive view of the sarcoma therapeutic landscape. Primary inputs included interviews with oncologists, clinical trial investigators, regulatory experts and market access professionals, ensuring that clinical practice patterns and payer expectations informed interpretation of scientific and operational trends. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidances, conference proceedings and technical drug development resources; these materials were triangulated to validate insights and to contextualize emerging therapeutic modalities.

Analytical methods combined qualitative thematic analysis with cross-sectional mapping of segmentation axes to reveal where biological plausibility, clinical need and operational feasibility intersect. Scenario analysis was used to explore the implications of supply chain shocks and tariff pressures on manufacturing and pricing strategies, while comparative benchmarking illuminated differentiators among developer archetypes. Throughout, emphasis was placed on transparent assumptions, reproducible workflows, and clear traceability between cited evidence and strategic conclusions. The methodology supports replicable updates as new clinical data, regulatory decisions or commercial developments emerge, enabling stakeholders to refresh strategies in response to evolving evidence.

Synthesis of strategic priorities for translating scientific advances into sustainable clinical impact while anticipating operational, regulatory and payer challenges in sarcoma

In closing, the sarcoma therapeutics arena presents a compelling mix of scientific opportunity and practical complexity. Progress in molecular characterization, immunotherapy design and combination approaches has expanded the set of viable therapeutic strategies, but success depends on disciplined alignment of clinical development, regulatory planning and commercial preparation. Robust segmentation-across drug class, indication, route of administration, treatment modality and end user-enables focused resource allocation and more efficient trial execution. Regional strategies must reflect differences in diagnostic capacity, regulatory pathways and payer expectations, and supply chain resilience is increasingly important in the face of tariff and geopolitical pressures.

Organizations that integrate translational science with adaptive trial design, build strategic partnerships to close capability gaps, and engage payers and patients early will be best positioned to translate innovation into sustained clinical and commercial impact. Thoughtful investment in evidence that demonstrates real-world value and in operations that secure reliable supply will accelerate adoption and improve outcomes for patients living with these rare and often aggressive diseases. The path forward requires both scientific rigor and pragmatic execution, and the recommendations offered here provide a framework to convert insight into effective action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sarcoma Drugs Market, by Drug Class

  • 8.1. Antiangiogenic Therapy
    • 8.1.1. PDGF Inhibitors
    • 8.1.2. VEGF Inhibitors
  • 8.2. Chemotherapy
    • 8.2.1. Alkylating Agents
    • 8.2.2. Anthracyclines
    • 8.2.3. Antimetabolites
    • 8.2.4. Topoisomerase Inhibitors
  • 8.3. Hormonal Therapy
  • 8.4. Immunotherapy
    • 8.4.1. Adoptive Cell Therapy
    • 8.4.2. Cancer Vaccines
    • 8.4.3. Checkpoint Inhibitors
    • 8.4.4. Cytokine Therapy
  • 8.5. Targeted Therapy
    • 8.5.1. CDK4/6 Inhibitors
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. PARP Inhibitors
    • 8.5.4. Tyrosine Kinase Inhibitors

9. Sarcoma Drugs Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Sarcoma Drugs Market, by Treatment Modality

  • 10.1. Combination Therapy
    • 10.1.1. Chemotherapy Plus Immunotherapy
    • 10.1.2. Chemotherapy Plus Targeted
    • 10.1.3. Immunotherapy Plus Targeted
  • 10.2. Monotherapy

11. Sarcoma Drugs Market, by Indication

  • 11.1. Bone Sarcoma
    • 11.1.1. Chondrosarcoma
    • 11.1.2. Ewing Sarcoma
    • 11.1.3. Osteosarcoma
  • 11.2. Gastrointestinal Stromal Tumors
  • 11.3. Kaposi Sarcoma
  • 11.4. Soft Tissue Sarcoma
    • 11.4.1. Leiomyosarcoma
    • 11.4.2. Liposarcoma
    • 11.4.3. Rhabdomyosarcoma
    • 11.4.4. Synovial Sarcoma

12. Sarcoma Drugs Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Sarcoma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sarcoma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sarcoma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sarcoma Drugs Market

17. China Sarcoma Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. AgonOx
  • 18.8. Amneal Pharmaceuticals LLC
  • 18.9. Aurobindo Pharma Limited
  • 18.10. Baxter International Inc.
  • 18.11. Bayer AG
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Daiichi Sankyo Company, Limited
  • 18.14. Eisai Co., Ltd.
  • 18.15. Eli Lilly and Company
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fresenius Kabi AG
  • 18.18. GlaxoSmithKline PLC
  • 18.19. Hikma Pharmaceuticals PLC
  • 18.20. Ipsen Pharma
  • 18.21. Johnson & Johnson Services, Inc.
  • 18.22. Karyopharm Therapeutics Inc.
  • 18.23. Lupin Limited
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. Sun Pharmaceutical Industries Limited
  • 18.28. TRACON Pharmaceuticals, Inc.
  • 18.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GCC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. GCC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. GCC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. GCC SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. GCC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 273. GCC SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 274. GCC SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. G7 SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. G7 SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. G7 SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. G7 SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. G7 SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. G7 SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. G7 SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. G7 SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. G7 SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 312. G7 SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 313. G7 SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. NATO SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 315. NATO SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. NATO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. NATO SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. NATO SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. NATO SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 322. NATO SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. NATO SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 325. NATO SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 326. NATO SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA SARCOMA DR